CN111247131A - 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物 - Google Patents

抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物 Download PDF

Info

Publication number
CN111247131A
CN111247131A CN201880070173.7A CN201880070173A CN111247131A CN 111247131 A CN111247131 A CN 111247131A CN 201880070173 A CN201880070173 A CN 201880070173A CN 111247131 A CN111247131 A CN 111247131A
Authority
CN
China
Prior art keywords
compound
isomer
iii
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880070173.7A
Other languages
English (en)
Other versions
CN111247131B (zh
Inventor
吴立方
孙飞
杜金华
丁照中
陈曙辉
张喜全
徐宏江
杨玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Medshine Discovery Inc
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Medshine Discovery Inc filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN111247131A publication Critical patent/CN111247131A/zh
Application granted granted Critical
Publication of CN111247131B publication Critical patent/CN111247131B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

一类抗HBV的四氢异噁唑并[4,3‑c]吡啶类化合物及其药学上可接受的盐或其异构体被公开，所述化合物由式（I）表示。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201880070173.7A 2017-11-16 2018-11-16 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物 Active CN111247131B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201711138922 2017-11-16
CN2017111389229 2017-11-16
CN2018103397232 2018-04-16
CN201810339723 2018-04-16
PCT/CN2018/115857 WO2019096241A1 (zh) 2017-11-16 2018-11-16 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物

Publications (2)

Publication Number Publication Date
CN111247131A true CN111247131A (zh) 2020-06-05
CN111247131B CN111247131B (zh) 2022-02-18

Family

ID=66540082

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880070173.7A Active CN111247131B (zh) 2017-11-16 2018-11-16 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物

Country Status (7)

Country Link
US (1) US11572372B2 (zh)
EP (1) EP3712139A4 (zh)
JP (1) JP7250015B2 (zh)
CN (1) CN111247131B (zh)
PH (1) PH12020550649A1 (zh)
SG (1) SG11202004594SA (zh)
WO (1) WO2019096241A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511747A (zh) * 2017-12-21 2020-08-07 爱尔兰詹森科学公司 用于治疗与hbv感染相关的疾病的异噁唑化合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210079015A1 (en) * 2017-11-17 2021-03-18 Novartis Ag Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
WO2020228745A1 (zh) * 2019-05-14 2020-11-19 正大天晴药业集团股份有限公司 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889953A (zh) * 2011-07-01 2014-06-25 肝炎与病毒研究所 作为防乙肝病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物
WO2016109689A2 (en) * 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
WO2016113273A1 (en) * 2015-01-16 2016-07-21 F. Hoffmann-La Roche Ag Pyrazine compounds for the treatment of infectious diseases
CN111315749A (zh) * 2017-11-17 2020-06-19 诺华股份有限公司 新颖的二氢异噁唑化合物及其在治疗乙型肝炎中的用途
CN111511747A (zh) * 2017-12-21 2020-08-07 爱尔兰詹森科学公司 用于治疗与hbv感染相关的疾病的异噁唑化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889953A (zh) * 2011-07-01 2014-06-25 肝炎与病毒研究所 作为防乙肝病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物
WO2016109689A2 (en) * 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
WO2016113273A1 (en) * 2015-01-16 2016-07-21 F. Hoffmann-La Roche Ag Pyrazine compounds for the treatment of infectious diseases
CN111315749A (zh) * 2017-11-17 2020-06-19 诺华股份有限公司 新颖的二氢异噁唑化合物及其在治疗乙型肝炎中的用途
CN111511747A (zh) * 2017-12-21 2020-08-07 爱尔兰詹森科学公司 用于治疗与hbv感染相关的疾病的异噁唑化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511747A (zh) * 2017-12-21 2020-08-07 爱尔兰詹森科学公司 用于治疗与hbv感染相关的疾病的异噁唑化合物

Also Published As

Publication number Publication date
EP3712139A4 (en) 2021-05-05
JP7250015B2 (ja) 2023-03-31
CN111247131B (zh) 2022-02-18
SG11202004594SA (en) 2020-06-29
US11572372B2 (en) 2023-02-07
PH12020550649A1 (en) 2021-04-26
EP3712139A1 (en) 2020-09-23
JP2021503466A (ja) 2021-02-12
US20200377517A1 (en) 2020-12-03
WO2019096241A1 (zh) 2019-05-23

Similar Documents

Publication Publication Date Title
US9938301B2 (en) Dihydropyrimido fused ring derivative as HBV inhibitor
KR102087397B1 (ko) B형 간염 바이러스의 표면항원 억제제
CN111247131B (zh) 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物
US11591334B2 (en) Substituted pyrrolizines for the treatment of hepatitis B
CN113501821B (zh) 具有mgat-2抑制活性的稠合环衍生物
JP7072003B2 (ja) Ｂ型肝炎ウイルス表面抗原阻害剤
US10889561B2 (en) Process of making somatostatin modulators
CN108884107B (zh) 乙型肝炎病毒表面抗原抑制剂
CN111344290A (zh) 作为Wee1抑制剂的大环类化合物及其应用
US20220073535A1 (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
TW202045516A (zh) 雙環磺醯胺
JP7329052B2 (ja) フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用
CN113825758B (zh) 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型
CN115677698B (zh) 一种高效抗病毒化合物及其用途
WO2018086530A1 (zh) 作为cccDNA抑制剂的磺酰胺类化合物
US20240352030A1 (en) N-substituted tetrahydrothienopyridine derivatives and uses thereof
CN114555076A (zh) 用于治疗非酒精性脂肪性肝炎的药物
CN117126162A (zh) 多取代杂环类化合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant